Shionogi's Anti-Obesity Drug S-2367 Phase IIb Shows Promising Results
This article was originally published in PharmAsia News
Executive SummaryShionogi announced May 13 that a Phase IIb analysis of anti-obesity drug S-2367 showed good results in both reduced calorie and low calorie tests. Following the analysis, Shionogi decided to continue the trials and plans to start Phase III trials during the second half of next year. Shionogi considers S-2367, which is being developed in the U.S., as one of its major products to expand overseas. Shionogi plans to obtain approval for the drug in 2011 and market it in 2013. The company is also looking for other companies to jointly develop and market the product. (Click here for more - Japanese language
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.